Reason for request
First listing
Summary of opinion
Favourable opinion for reimbursement “for diagnostic use only, in adults and children aged 2 years and older for contrast-enhanced magnetic resonance imaging (MRI) to improve detection and visualisation of pathologies with disruption of the blood-brain-barrier (BBB) and/or abnormal vascularity of:
- the brain, spine, and associated tissues of the central nervous system (CNS);
- the liver, kidney, pancreas, breast, lung, prostate, and musculoskeletal system.
VUEWAY should be used only when diagnostic information is essential and not available with unenhanced MRI”.
Clinical Benefit
| Substantial |
The clinical benefit of VUEWAY (gadopiclenol) 0.5 mmol/mL solution for injection is substantial in the MA indications. |
Clinical Added Value
| no clinical added value |
Considering:
- evidence of a non-inferiority of MRI with injection of VUEWAY (gadopiclenol) at a dose of 0.05 mmol/kg compared to injection of gadobutrol at a dose of 0.1 mmol/kg, on 3 coprimary endpoints for visualisation of lesions in the CNS and body, in the PICTURE and PROMISE studies conducted in adults,
- the pharmacokinetic profile in children similar to that observed in adults,
but:
- the absence of comparison in the paediatric study and robust efficacy and safety data,
- the limited safety data in terms of follow-up duration, limiting monitoring of the occurrence of adverse events (AE) such as retention of gadolinium in the brain or nephrogenic systemic fibrosis (NSF), an AE associated with the administration of a gadolinium-based contrast agent, the symptoms of which can develop several weeks to several months after its administration,
the Committee deems that VUEWAY (gadopiclenol) 0.5 mmol/mL solution for injection provides no clinical added value (CAV V) compared with gadobutrol. |
Avis rectifié en date du 26/11/2024
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
PqFTR1S2bHfaRFJa
Listen
